Search Within

Kenneth Ho-Ming Yu

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (22)
Groups
  1. Center for Pancreatic Cancer Research (48)
  2. Department of Medicine (48)
  3. GSK Faculty (48)
  4. Gastrointestinal Oncology Service (48)
  5. Human Oncology and Pathogenesis Program (48)
  6. Solid Tumor Oncology Division (48)

More Groups

People
  1. Eileen O'Reilly (42)
  2. Anna Varghese (28)
  3. Christine Iacobuzio-Donahue (28)
  4. Marinela Capanu (24)
  5. Wungki Park (22)
  6. Joanne Chou (21)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (6)
  4. 2022 (6)
  5. 2021 (4)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Clinical Cancer Research (6)
  3. Cancer (3)
  4. JNCI: Journal of the National Cancer Institute (3)
  5. Annals of Oncology (2)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. American Association for Cancer Research (9)
  3. Oxford University Press (5)
  4. Wiley Blackwell (4)
  5. Springer (2)
  6. Adis Data Information Bv (1)

More Publishers

Results (48)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: Clinical insights and genomic features from a large contemporary cohort
    Journal Article

    Keane, F.; O’Connor, C.; Moss, D.; Chou, J. F.; Perry, M. A.; Crowley, F.; Saxena, P.; Chan, A.; Schoenfeld, J. D.; Singhal, A.; more...
    JNCI: Journal of the National Cancer Institute (2025)

    Fulltext@MSK | Save
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Precision medicine for pancreatic cancer: Characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease
    Journal Article

    Keane, F.; Chou, J. F.; Walch, H.; Schoenfeld, J.; Singhal, A.; Cowzer, D.; Harrold, E.; O'Connor, C. A.; Park, W.; Varghese, A.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes
    Meeting Abstract

    Keane, F.; Moss, D.; O'Connor, C. A.; Perry, M.; Chou, J. F.; Crowley, F.; Saxena, P.; Chan, A.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC)
    Meeting Abstract

    Keane, F.; Saadat, L.; O'Connor, C.; Chou, J. F.; Brannon, A. R.; Cowzer, D.; Crowley, F.; Debnath, N.; Bowman, A.; Xu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC)
    Meeting Abstract

    Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO)
    Meeting Abstract

    Keane, F.; Balogun, F.; O'Connor, C.; Crowley, F.; Chan, A.; Cowzer, D.; Chou, J. F.; Park, W.; Varghese, A. M.; Yu, K. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer
    Meeting Abstract

    Reyngold, M.; Wei, A.; O'Reilly, E. M.; D'Angelica, M. I.; Drebin, J. A.; Soares, K.; Kingham, T. P.; Balachandran, V. P.; Varghese, A. M.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save